ReviewMedical science monitor : international medical journal of experimental and clinical research2025
A Review of the Diagnosis, Risk Factors, and Role of Angiogenetic Factors in Hypertensive Disorders of Pregnancy.
Review in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive disorders in pregnancy (HDPs) include chronic hypertension, gestational hypertension, preeclampsia, and chronic hypertension with superimposed preeclampsia and are major causes of maternal and fetal complications. Preeclampsia, in particular, poses significant risks, yet prevention and management remain challenging despite extensive research. Various risk factors have been identified, with obesity being a key contributor to preeclampsia. The role of angiogenic factors, specifically soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), has gained more attention in hopes of better understanding the pathogenesis of preeclampsia. Imbalances in these factors - increased sFlt-1 and decreased PlGF levels - can be observed before the clinical onset of the disease. The sFlt-1/PlGF ratio has been demonstrated to have strong predictive value in ruling out preeclampsia within the next 7 days for women with suspected cases, enhancing early diagnosis and screening mechanisms. Furthermore, women with a history of hypertensive disorders during pregnancy face a significantly higher risk of developing postpartum hypertension, especially within the first 2 years following childbirth. This article aims to provide a comprehensive review of HDPs, focusing on risk factors, diagnostic criteria, and the emerging role of angiogenic biomarkers. Specifically, it highlights the potential of the sFlt-1/PlGF ratio as a noninvasive tool to improve the early detection and diagnosis of preeclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.